See more : Eagle Financial Services, Inc. (EFSI) Income Statement Analysis – Financial Results
Complete financial analysis of Avis Budget Group, Inc. (CAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avis Budget Group, Inc., a leading company in the Rental & Leasing Services industry within the Industrials sector.
You may be interested
- Adyen N.V. (1N8.DE) Income Statement Analysis – Financial Results
- Sub Sri Thai Real Estate Investment Trust (SSTRT.BK) Income Statement Analysis – Financial Results
- Himalaya Shipping Ltd (J1X.SG) Income Statement Analysis – Financial Results
- Naked Wines plc (NWINF) Income Statement Analysis – Financial Results
- Shenzhen Capchem Technology Co., Ltd. (300037.SZ) Income Statement Analysis – Financial Results
Avis Budget Group, Inc. (CAR)
About Avis Budget Group, Inc.
Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.01B | 11.99B | 9.31B | 5.40B | 9.17B | 9.12B | 8.85B | 8.66B | 8.50B | 8.49B | 7.94B | 7.36B | 5.90B | 5.19B | 5.13B | 5.98B | 6.03B | 5.69B | 18.24B | 19.79B | 18.19B | 14.09B | 8.95B | 3.93B | 5.40B | 5.28B | 5.31B | 2.35B | 1.42B | 1.04B | 875.00M | 738.90M | 641.30M | 450.80M | 365.00M | 268.60M | 195.30M | 138.30M | 84.20M |
| Cost of Revenue | 7.24B | 1.23B | 1.51B | 1.69B | 2.41B | 2.49B | 2.51B | 2.33B | 2.22B | 2.29B | 2.08B | 1.77B | 1.51B | 1.59B | 1.72B | 2.01B | 1.93B | 1.74B | 10.68B | 10.34B | 9.41B | 6.72B | 2.94B | 1.31B | 1.10B | 609.20M | -184.00M | -3.00M | -74.00M | -95.70M | -94.70M | -109.10M | -106.70M | -73.00M | 128.50M | 10.40M | 16.90M | 900.00K | 2.40M |
| Gross Profit | 4.77B | 10.76B | 7.80B | 3.72B | 6.77B | 6.63B | 6.34B | 6.33B | 6.28B | 6.21B | 5.86B | 5.59B | 4.39B | 3.59B | 3.41B | 3.97B | 4.10B | 3.95B | 7.55B | 9.45B | 8.78B | 7.37B | 6.01B | 2.62B | 4.31B | 4.67B | 5.50B | 2.35B | 1.49B | 1.14B | 969.70M | 848.00M | 748.00M | 523.80M | 236.50M | 258.20M | 178.40M | 137.40M | 81.80M |
| Gross Profit Ratio | 39.69% | 89.74% | 83.79% | 68.79% | 73.76% | 72.68% | 71.67% | 73.08% | 73.86% | 73.09% | 73.86% | 75.97% | 74.42% | 69.32% | 66.50% | 66.35% | 68.04% | 69.48% | 41.41% | 47.75% | 48.28% | 52.29% | 67.18% | 66.56% | 79.69% | 88.47% | 103.46% | 100.13% | 105.23% | 109.16% | 110.82% | 114.77% | 116.64% | 116.19% | 64.79% | 96.13% | 91.35% | 99.35% | 97.15% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.49B | 1.28B | 1.06B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 583.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 0.00 | 0.00 | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Selling & Marketing | -81.00M | 64.00M | 81.00M | 54.00M | 121.00M | 116.00M | 111.00M | 127.00M | 123.00M | 112.00M | 116.00M | 127.00M | 0.00 | -14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.71B | 2.01B | 1.76B | 1.39B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.41B | 1.35B | 1.15B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 569.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 1.99B | 1.20B | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Other Expenses | 0.00 | 5.51B | 4.53B | 3.54B | 4.95B | 4.90B | 4.75B | 4.61B | 4.50B | 4.43B | 4.23B | 3.95B | 3.12B | 2.71B | 2.73B | 3.24B | 3.12B | 2.99B | 1.57B | 3.06B | 3.01B | 2.56B | 2.30B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| Operating Expenses | 1.58B | 6.86B | 5.67B | 4.25B | 6.19B | 6.05B | 5.81B | 5.68B | 5.54B | 5.51B | 5.22B | 4.86B | 3.88B | 3.28B | 3.27B | 3.89B | 3.78B | 3.81B | 5.35B | 6.64B | 6.13B | 5.07B | 4.31B | 1.40B | 2.76B | 3.41B | 3.99B | 1.90B | 1.22B | 949.90M | 827.10M | 746.50M | 664.50M | 481.30M | 208.80M | 274.60M | 147.80M | 122.10M | 73.90M |
| Cost & Expenses | 8.82B | 8.09B | 7.18B | 5.93B | 8.59B | 8.55B | 8.31B | 8.02B | 7.76B | 7.80B | 7.30B | 6.63B | 5.39B | 4.87B | 4.98B | 5.90B | 5.70B | 5.55B | 16.03B | 16.97B | 15.54B | 11.79B | 7.25B | 2.72B | 3.85B | 4.02B | 3.81B | 1.90B | 1.14B | 854.20M | 732.40M | 637.40M | 557.80M | 408.30M | 337.30M | 285.00M | 164.70M | 123.00M | 76.30M |
| Interest Income | 0.00 | 1.00M | 1.00M | 12.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 296.00M | 250.00M | 218.00M | 231.00M | 178.00M | 188.00M | 188.00M | 203.00M | 194.00M | 209.00M | 228.00M | 268.00M | 219.00M | 162.00M | 153.00M | 129.00M | 127.00M | 236.00M | 1.34B | 251.00M | 797.00M | 1.27B | 1.84B | 401.00M | 3.93B | 1.46B | 2.36B | 340.80M | 8.70M | 0.00 | 0.00 | 2.10M | 60.80M | 11.00M | 15.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.45B | 2.81B | 2.48B | 2.56B | 3.14B | 2.23B | 2.21B | 2.13B | 163.00M | 2.02B | 128.00M | 109.00M | 95.00M | 90.00M | 96.00M | 1.73B | 1.65B | 1.47B | 1.29B | 3.20B | 3.46B | 2.72B | 2.17B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| EBITDA | 6.43B | 7.15B | 4.74B | 2.17B | 3.96B | 2.99B | 2.88B | 2.98B | 794.00M | 2.92B | 477.00M | 693.00M | 350.00M | 332.00M | 172.00M | 841.00M | 1.10B | 1.35B | 1.73B | 1.31B | 6.18B | 5.01B | 3.88B | 1.64B | 4.54B | 3.69B | 4.65B | 1.32B | 729.00M | 569.30M | 475.90M | 407.70M | 383.50M | 250.60M | 187.80M | 116.20M | 74.50M | 54.10M | 31.30M |
| EBITDA Ratio | 53.57% | 34.50% | 25.80% | -5.72% | 8.57% | 8.46% | 8.31% | 9.68% | 10.62% | 31.98% | 9.69% | 11.42% | 10.34% | 7.89% | 4.74% | 30.17% | 32.76% | 28.30% | 24.39% | 30.30% | 33.95% | 38.23% | 51.73% | 41.78% | 84.04% | 69.80% | 87.55% | 56.28% | 51.52% | 54.49% | 54.39% | 55.18% | 59.80% | 55.59% | 51.45% | 42.07% | 38.15% | 39.12% | 37.17% |
| Operating Income | 3.19B | 3.91B | 2.13B | -529.00M | 579.00M | 516.00M | 476.00M | 585.00M | 685.00M | 696.00M | 617.00M | 715.00M | 515.00M | 305.00M | 129.00M | 76.00M | 325.00M | 143.00M | 866.00M | 2.80B | 2.71B | 1.03B | 2.46B | 1.31B | 3.47B | 2.11B | 2.66B | 617.00M | 275.10M | 190.50M | 138.30M | 98.20M | 105.90M | 39.80M | 29.50M | -19.60M | 27.40M | 11.80M | 7.00M |
| Operating Income Ratio | 26.57% | 32.62% | 22.88% | -9.79% | 6.31% | 5.66% | 5.38% | 6.76% | 8.06% | 8.20% | 7.77% | 9.72% | 8.73% | 5.88% | 2.51% | 1.27% | 5.39% | 2.51% | 4.75% | 14.15% | 14.92% | 7.30% | 27.51% | 33.38% | 64.25% | 39.85% | 49.99% | 26.28% | 19.44% | 18.23% | 15.81% | 13.29% | 16.51% | 8.83% | 8.08% | -7.30% | 14.03% | 8.53% | 8.31% |
| Total Other Income/Expenses | -1.28B | -270.00M | -423.00M | -965.00M | -280.00M | -499.00M | -623.00M | -606.00M | -303.00M | -577.00M | -520.00M | -415.00M | -479.00M | -247.00M | -206.00M | -1.42B | -1.32B | -820.00M | -213.00M | 1.77B | -445.00M | -700.00M | -1.05B | -354.00M | -2.18B | -1.00B | -754.70M | -170.40M | -4.40M | 0.00 | -400.00K | -5.40M | -38.40M | -13.70M | -13.90M | 1.80M | 4.00M | 4.30M | -700.00K |
| Income Before Tax | 1.91B | 3.64B | 1.71B | -956.00M | 287.00M | 267.00M | 211.00M | 279.00M | 382.00M | 392.00M | 97.00M | 300.00M | 36.00M | 72.00M | -77.00M | -1.34B | -992.00M | -677.00M | 1.35B | 2.55B | 2.21B | 1.64B | 658.00M | 885.00M | -635.00M | 264.40M | 294.70M | 276.20M | 266.40M | 190.50M | 142.20M | 96.10M | 45.10M | 28.80M | 13.80M | -14.60M | 31.40M | 16.10M | 7.20M |
| Income Before Tax Ratio | 15.94% | 30.32% | 18.34% | -17.70% | 3.13% | 2.93% | 2.38% | 3.22% | 4.49% | 4.62% | 1.22% | 4.08% | 0.61% | 1.39% | -1.50% | -22.47% | -16.46% | -11.90% | 7.38% | 12.88% | 12.15% | 11.62% | 7.35% | 22.52% | -11.75% | 5.00% | 5.54% | 11.76% | 18.83% | 18.23% | 16.25% | 13.01% | 7.03% | 6.39% | 3.78% | -5.44% | 16.08% | 11.64% | 8.55% |
| Income Tax Expense | 279.00M | 880.00M | 425.00M | -272.00M | -15.00M | 102.00M | -150.00M | 116.00M | 69.00M | 147.00M | 81.00M | 10.00M | 65.00M | 18.00M | -30.00M | -219.00M | -45.00M | -226.00M | 474.00M | 728.00M | 745.00M | 556.00M | 235.00M | 309.00M | -406.00M | 104.50M | 239.30M | 112.10M | 103.00M | 72.90M | 54.80M | 37.30M | 20.00M | 11.30M | 5.70M | -3.30M | 14.00M | 7.40M | 4.40M |
| Net Income | 1.63B | 2.76B | 1.29B | -684.00M | 302.00M | 165.00M | 361.00M | 163.00M | 313.00M | 245.00M | 16.00M | 290.00M | -29.00M | 54.00M | -47.00M | -1.12B | -916.00M | -1.99B | 1.34B | 2.08B | 1.17B | 846.00M | 385.00M | 602.00M | -55.00M | 539.60M | 55.40M | 164.10M | 163.40M | 117.60M | 87.40M | 58.80M | 25.10M | 17.50M | 8.10M | -11.30M | 17.40M | 8.70M | 2.80M |
| Net Income Ratio | 13.59% | 23.04% | 13.80% | -12.66% | 3.29% | 1.81% | 4.08% | 1.88% | 3.68% | 2.89% | 0.20% | 3.94% | -0.49% | 1.04% | -0.92% | -18.81% | -15.20% | -35.05% | 7.35% | 10.52% | 6.44% | 6.01% | 4.30% | 15.32% | -1.02% | 10.21% | 1.04% | 6.99% | 11.55% | 11.26% | 9.99% | 7.96% | 3.91% | 3.88% | 2.22% | -4.21% | 8.91% | 6.29% | 3.33% |
| EPS | 42.61 | 58.44 | 19.80 | -9.70 | 4.02 | 2.08 | 4.32 | 1.78 | 3.02 | 2.32 | 0.15 | 2.72 | -0.28 | 0.53 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 20.29 | 11.50 | 7.57 | 4.20 | 8.40 | -0.73 | 6.40 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| EPS Diluted | 42.06 | 57.11 | 19.44 | -9.70 | 3.99 | 2.06 | 4.25 | 1.75 | 2.98 | 2.22 | 0.15 | 2.42 | -0.28 | 0.49 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 19.66 | 11.30 | 7.57 | 4.10 | 8.10 | -0.73 | 6.10 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| Weighted Avg Shares Out | 38.30M | 47.30M | 64.90M | 70.50M | 75.20M | 79.30M | 83.40M | 92.00M | 103.40M | 105.40M | 107.60M | 106.60M | 105.20M | 103.10M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 101.91M | 111.76M | 91.67M | 71.67M | 75.10M | 84.38M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
| Weighted Avg Shares Out (Dil) | 38.80M | 48.40M | 66.10M | 70.50M | 75.70M | 80.10M | 84.80M | 93.30M | 105.00M | 110.60M | 111.40M | 121.60M | 105.20M | 126.70M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 103.72M | 111.76M | 93.90M | 74.32M | 75.10M | 88.52M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
New Strong Sell Stocks for October 15th
AMTB, CAR and BSET have been added to the Zacks Rank #24 (Strong Sell) List on October 15, 2024.
New Strong Sell Stocks for October 11th
ALLY, CAR and DNOW have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2024.
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma.
EV Nickel Intersects 3 New Zones of Mineralization on the Carlang Trend Including Highest Nickel Grades to Date & Significantly Extends Strike Length by 7km
Maiden diamond drill program on CarLang B, C and E Zones intersected significant near surface mineralization CarLang C encountered highest grades to date on the CarLang Trend and covers an area approximately twice the size as the Company's CarLang A...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studies Lead site Memorial Sloan Kettering...
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of...
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results...
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference
SAN JOSE, Calif. , Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer Research Alliance's...
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™.
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is...
Source: https://incomestatements.info
Category: Stock Reports